Skip to search formSkip to main contentSkip to account menu

MK 0991

Known as: MK-0991 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
The objective of the present study was to investigate the influence of the new echinocandins caspofungin (MK-0991) and… 
2003
2003
synthase have been discovered, including lipopeptides (pneumocandins and echinocandins), glycolipids (papulacandins) and… 
Highly Cited
2001
Highly Cited
2001
ABSTRACT The pharmacokinetics of the antifungal echinocandin-lipopeptide caspofungin (MK-0991) in plasma were studied in groups… 
2000
2000
ABSTRACT There have been several reports that the activity of echinocandin antifungal agents is not affected or decreased in the… 
Review
2000
Review
2000
RISING INCIDENCE: In the past two decades, systemic fungal infections, essentially invasive candidiasis, but also invasive… 
1999
1999
  • A. GrollT. Walsh
  • 1999
  • Corpus ID: 25325816
Merck is developing the echinocandin-type antifungal, MK-0991 (L-743872), a beta-1,3-glucan synthesis inhibitor. It is currently… 
1999
1999
  • N. Ryder
  • 1999
  • Corpus ID: 35983306
Genetic and genomic approaches to discovery, selection and evaluation of antifungal targets were extensively discussed by several… 
1998
1998
ABSTRACT A binding enzyme-linked immunosorbent assay (ELISA) has been developed for measuring nanogram concentrations of…